<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="courier ; font-style : italic;} Clin Infect DisClin. Infect. DiscidClinical" exact="Infectious" post="Diseases: An Official Publication of the Infectious Diseases Society"/>
 <result pre="DisClin. Infect. DiscidClinical Infectious Diseases: An Official Publication of the" exact="Infectious" post="Diseases Society of America1058-48381537-6591Oxford University PressUS pmcid: 7108130 pmid:"/>
 <result pre="Infect. DiscidClinical Infectious Diseases: An Official Publication of the Infectious" exact="Diseases" post="Society of America1058-48381537-6591Oxford University PressUS pmcid: 7108130 pmid: 32150618"/>
 <result pre="of Optimized Dosing Design of Hydroxychloroquine for the Treatment of" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) YaoXueting1YeFei2ZhangMiao1CuiCheng1HuangBaoying2NiuPeihua2LiuXu1ZhaoLi2DongErdan3SongChunli4ZhanSiyan5LuRoujian2LiHaiyan13TanWenjie2LiuDongyang1[1], Drug Clinical"/>
 <result pre="Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) YaoXueting1YeFei2ZhangMiao1CuiCheng1HuangBaoying2NiuPeihua2LiuXu1ZhaoLi2DongErdan3SongChunli4ZhanSiyan5LuRoujian2LiHaiyan13TanWenjie2LiuDongyang1[1], Drug Clinical Trial"/>
 <result pre="Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SARS-CoV-2) YaoXueting1YeFei2ZhangMiao1CuiCheng1HuangBaoying2NiuPeihua2LiuXu1ZhaoLi2DongErdan3SongChunli4ZhanSiyan5LuRoujian2LiHaiyan13TanWenjie2LiuDongyang1[1], Drug Clinical Trial Center,"/>
 <result pre="Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SARS-CoV-2) YaoXueting1YeFei2ZhangMiao1CuiCheng1HuangBaoying2NiuPeihua2LiuXu1ZhaoLi2DongErdan3SongChunli4ZhanSiyan5LuRoujian2LiHaiyan13TanWenjie2LiuDongyang1[1], Drug Clinical Trial Center, Peking"/>
 <result pre="Third Hospital,China[2], MHC Key Laboratory of Biosafety, National Institute for" exact="Viral" post="Disease Control and Prevention,ChinaChina[3], Department of Cardiology and Institute"/>
 <result pre="Hospital,China[2], MHC Key Laboratory of Biosafety, National Institute for Viral" exact="Disease" post="Control and Prevention,ChinaChina[3], Department of Cardiology and Institute of"/>
 <result pre="Disease Control and Prevention,ChinaChina[3], Department of Cardiology and Institute of" exact="Vascular" post="Medicine, Peking University Third Hospital,China[4], Department of Orthopedics, Peking"/>
 <result pre="the original work is properly cited.ciaa237.pdf Abstract Abstract Background The" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) first broke out"/>
 <result pre="original work is properly cited.ciaa237.pdf Abstract Abstract Background The Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) first broke out in"/>
 <result pre="work is properly cited.ciaa237.pdf Abstract Abstract Background The Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SARS-CoV-2) first broke out in Wuhan"/>
 <result pre="is properly cited.ciaa237.pdf Abstract Abstract Background The Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SARS-CoV-2) first broke out in Wuhan (China)"/>
 <result pre="tolerable safety profile makes it the preferred drug to treat" exact="malaria" post="and autoimmune conditions. We propose that the immunomodulatory effect"/>
 <result pre="profile makes it the preferred drug to treat malaria and" exact="autoimmune" post="conditions. We propose that the immunomodulatory effect of hydroxychloroquine"/>
</results>
